智通财经APP获悉，荣昌生物(09995)午后跌超4%，截至发稿，跌3.89%，报17.28港元，成交额7692.38万港元。
消息面上，荣昌生物此前公司年度财报快报，按中国会计准则，实现营业总收入17.15亿人民币，同比增加58.4%，主要受惠注射用泰它西普和注射用维迪西妥单抗销量增加。亏损由上年度15.11亿元，收窄至14.68亿元。
值得注意的是，2月4日，辉瑞宣布计提29亿美元的无形资产减值，其中包括从荣昌生物引进的维迪西妥单抗计提2亿美元减值。2月6日，荣昌生物执行董事兼核心技术人员何如意宣布辞职，令市场猜测公司技术研发布局面临调整。2月16日，荣昌生物关联公司迈百瑞IPO进程终止，市场担忧迈百瑞资金紧张将影响到双方后续的合作项目推进。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.